Carboplatin (NSC 241240)

製品コード:S1215 別名:JM-8, CBDCA

For research use only.

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Carboplatin (NSC 241240)化学構造

CAS No. 41575-94-4

サイズ 価格(税別)
JPY 14700
JPY 19700
JPY 29700

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(89)

製品安全説明書

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

生物活性

製品説明 Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
特性 This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
ターゲット
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
体外試験

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrudWpFOi1{NfMAje69VQ>? NFvSdXA4OiCq M2TuR4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NEPjV5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|ExPSd-Mk[xN|cyODV:L3G+
Tca8113/CBP  NYLPVVl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[yMVI26oDLzszN NV74dZIxPzJiaB?= NWju[5EycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MoPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
Tca8113/PYM  M1m4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m0WVIuOjYkgJpOwG0> NGDYW5o4OiCq M1X3bIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
SKOV3 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P6[FYxKG2pL33s M{e1cVEuPSCm NY[xVZpOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= MnTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewOFMoRjJ4MUO3NFQ{RC:jPh?=
SKOV3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMVQh|rypL33s NF:3NlIzPC92OD:3NkBp M3\sT4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkWyO|MoRjJ4MUK1Nlc{RC:jPh?=
SKOV3 MYrBdI9xfG:|aYOgRZN{[Xl? NWXyXmFGOiEQvHevcYw> MkLDOFghcA>? NF3PPJZqdmS3Y3XzJIFxd3C2b4Ppdy=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO|M9N2F-
OSA NVXT[o5rS2yxbn;n[Y5q[yCDc4PhfS=> M{nkcFIvPS93IN88US=> NWj1VolJemW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= Mk[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUC2NlAoRjJ4MUGwOlIxRC:jPh?=
A549 MXfGeYN1cW:wIFHzd4F6 MlSzNE8zPS93MDFOwG0> NYfofZl5OjRiaB?= M17qS4Rwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= NFHPN3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
H1975 MU\GeYN1cW:wIFHzd4F6 MV2wM|I2NzVyIN88US=> NHnscJgzPCCq NYrodo1b\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NGnSd209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
A549 NYr2PZdXTnWldHnvckBCe3OjeR?= MY[wM|I2NzVyIN88US=> MorUNlQhcA>? NYS4UoNCfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w NGHVfnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
H1975 MULGeYN1cW:wIFHzd4F6 NFjheW8xNzJ3L{WwJO69VQ>? NXvteY1[OjRiaB?= M{\oepVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
A549 MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYeyOUDPxE1? NHHodZkzPCCq NY\DcoZtcW6qaXLpeJMh[2WubDDndo94fGh? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 NIjsepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXeyOUDPxE1? M3rFU|I1KGh? M4DFcolvcGmkaYTzJINmdGxiZ4Lve5Rp NYjDfpg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
MDA-MB-231 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC4eJcxNTJ{MDFOwIcwdWx? NFq3VnM4OiCq NHLseJZKSzVywrC9JFg3KM7:TR?= NXzBOZBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N|c3QTFpPkK1PFM4PjlzPD;hQi=>
T47D M3LlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\6XGh3OC1{MkCg{txoN22u MU[3NkBp M2GwbmlEPTEEoE2gOFgvQSEQvF2= MnexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{e2PVEoRjJ3OEO3OlkyRC:jPh?=
LCTCC NUHaTHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u3XmlEPTB;Mz645qCKyrWP MnfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MCTCC MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwOPMAjeK2VQ>? MlzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MegTCC MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm0XHhYUUN3ME20MlHjiIoEtV2= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTLTWM2OD13LkdihKnDvU1? MljZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MCF7 NETYVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDkVI4zOCEQvF2= NWHuUZcxPzJiaB?= MYPpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> M4\V[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[5NFI2Lz5{NUe2PVAzPTxxYU6=
A-549  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\xNZRvOC53IN88US=> NGq5fYozPCCq NF7mOnhFVVORwrC= MWrpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M{HiS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
A-549  MYfBdI9xfG:|aYOgRZN{[Xl? Mn\5NE42KM7:TR?= MnzuOFghcA>? M{LxeWROW00EoB?= NUnXbIlVe2ixd4Og[YFzdHliYYDvdJRwe2m|IH\lZZR2emW|IHnuZ4x2\GmwZzDicIVj[mmwZzDhcoQh[2i{b33heIlvKGOxbnTlcpNifGmxbh?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549  NIC1SXZHfWO2aX;uJGF{e2G7 MWqwMlUh|ryP MYm0PEBp MV7EUXNQyqB? MlzXd4hwf3NiYXLldpJidnRibXnjdo91fWK3bHWg[Il{enWydHnvci=> MkO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549  MUDGeYN1cW:wIFHzd4F6 NGLGUXYxNjVizszN MVu0PEBp NWDqenhrTE2VT9Mg NVGwU5JMcW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
RMG-1 M17LPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ6LkigxtEhOy54IH3nM2w> MoS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
FN-RMG-1 NIjpfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
RMG-1-hFUT MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTV6LkGgxtEhOi52IH3nM2w> M1;peVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K2PVE{Lz5{NUeyOlkyOzxxYU6=
FN-RMG-1-hFUT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTjSmpEUUN3ME2xNVgvQCEEsTCxN{45KG2pL1y= NHzZdVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOlkyOyd-MkW3NlY6OTN:L3G+
CHP-134  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7pcY81OSEQvF2= MX3EUXNQyqB? NGLNSphqdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32 M4nkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr3THlFOSEQvF2= M2iyPWROW00EoB?= NI\PSYlqdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? M{X2eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
CHP-134  M2DR[GZ2[3Srb36gRZN{[Xl? NF3GPYIyOCEQvF5CpC=> M3:wfmROW00EoB?= NVHrW2FncW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? M3z1S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32 NVnlenBQTnWldHnvckBCe3OjeR?= MYSxNEDPxE4EoB?= NIezVJlFVVORwrC= MUDpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh|MEO3NS=> Ml3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
A549 M{DZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LrUlAvOi12MECwJO69VQ>? NVLL[YFiPzJiaB?= MljUTWM2OD1zMk[gxtEhPS5yIN88US=> MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549/CDDP NHj1eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvncXdCOC5{LUSwNFAh|ryP NWnJd2doPzJiaB?= NVzkPId{UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= NGjKVZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
H460  NFrjfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H6TVI1KGh? MVLEUXNQ NVLHZVEzUUN3ME23Mlkh|ryP MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7OUm5OUc,OjV3OUm5PVU9N2F-
H460  MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfKVZg4NjlizszN MmXQNlQhcA>? NHXuO5JFVVOR MYHzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? MlvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
NRK-52E NWLtb|JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTmU2QyPzMEoHlCpC=> MVTJR|UxRTFyMDFCtUAyOi57IN88US=> NGXDTlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2OVYxOyd-MkW1OlU3ODN:L3G+
RGE NXXzZYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\YO|LDqGkEoB?= M2LteGlEPTB;MkKgxtEhPy52IN88US=> MoW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
NRK-52E NIDOSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NuKhcMLi NVPm[4xZUUN6ME2xO|khyrFiOT61JO69VQ>? NFnGbnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2OVYxOyd-MkW1OlU3ODN:L3G+
RGE NEDIPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7HO|LDqGkEoB?= MV;JR|gxRTZ|INMxJFcvPCEQvF2= NX7qb4hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
SK-OV-3 NHzZT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LDRlczKGh? MXLJR|UxRTFyND64JO69VQ>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
ES-2 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HZPVczKGh? MXjJR|UxRTF2Lk[g{txO NWDMbXJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
OVCAR-8 NXjrUIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm4bZVZPzJiaB?= NVTvcGFSUUN3ME25Ok4xKM7:TR?= NV;KNlI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
3AO NGTYcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrTO|IhcA>? MmH3TWM2OD14Mz60JO69VQ>? M1;pelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
A2780 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17pSlczKGh? NFzsc4xKSzVyPUG0OU44KM7:TR?= M2WyeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
SW626 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKxSXh2PzJiaB?= NEK2NXFKSzVyPUm3MlAh|ryP NWLTcopSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
OVCAR-3 NGDXcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;vR4k4OiCq NYjtOYtyUUN3ME2zNk43KM7:TR?= NV3RSJo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
A549 NIXn[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPqeVNqUUN3ME2xOVEvPTZiwsGgOVMvODZizszN MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
4T1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\KOpZKSzVyPUi0MlYzKMLzIEOwMlA2KM7:TRqg{txO MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
BALB/3T3 NWLpNmdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnIfXZ[UUN3ME2xOE4{OCEEsTC2MlY5KM7:TR?= M1XvXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
B16 M4TMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXIeFhKSzVyPU[0MlMxKMLzIE[uPFEh|ryP M1\DZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
DU 145 NYP1bZp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fKVGlEPTB;M{WuNFQhyrFiMUeuOVQh|ryP NYDHeZJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
FaDu NFruW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HaNWlEPTB;NEWuN|khyrFiMUGuOVAh|ryP NYfmWVR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HCV-29T M2PNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjmUItKSzVyPUS4MlU4KMLzIEKyMlQ6KM7:TR?= NVTCZXdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HL-60 M2W1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7hfYxKSzVyPUGxMlExKMLzIESuOFch|ryP MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HT-29 M3HrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf1blVKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
H146 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTR7LkdCtVE{NjFizszN MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H187 NWrCZ5MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoewTWM2OD1zMj63xtEzNjdizszN M1;oT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H128 M1Pnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;lTWM2OD1zME[uOOKyQS54IN88US=> NUPvSmxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H69 NIHKZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz6TWM2OD15Nj65xtEzPy56IN88US=> NVG0bY86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H209 NVHLSVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ3OD6xxtE6QS56IN88US=> MkiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS153 M3rJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTV5LklCtVkvOiEQvF2= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H526 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\WTmNyUUN3ME23MlLDuTFwNzFOwG0> NWjjOnplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS114 NI\rSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH3cXlOUUN3ME24OU45yrFzMj64JO69VQ>? NGnuN4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
DMS53 NWTmU3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF2Nj6yxtE{Pi52IN88US=> M3\me|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
HeLa MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;EOU05OCEQvF2= NHzVTY9qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N|YxRC:jPh?=
MCF-7 NGq4XItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i1RVUuQDBizszN NFLye45qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NHXxeWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
MDA-MB-231 M1PkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi5Z2I2NThyIN88US=> MXvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M3\lUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|YxLz5{NUGwPVM3ODxxYU6=
CaOV3 NXTldIlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK3NkBp M{flWGlEPTB;OE[uNUDPxE1? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-3 NGX1RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2b|k4OiCq NHHOOphKSzVyPUG3PU42KM7:TR?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-5 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjsZXA4OiCq MX;JR|UxRTd3Lkeg{txO M3TKdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
SKOV-3 M4XNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnqO|IhcA>? MorhTWM2OD13MESg{txO MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-4 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW3NkBp M2j3XmlEPTB;MkmwMlYh|ryP MonoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-8 M1TOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp NGG4U3BKSzVyPU[5NE4zKM7:TR?= Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
MA148 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQZ246OjRiaB?= NYnDOWFVUUN3ME24N{436oDLwsJihKkyNjRizsznM41t M{nTTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549 M2\QSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XWWlI1KGh? M123OGlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231 NYDo[nZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Twb|I1KGh? Ml\WTWM2OD15NEiuNQKBkcLz4pEJNU4yKM7:Zz;tcC=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
NCI-ADR/RES  M4fYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy3fYJZOjRiaB?= M1zGd2lEPTB;MUe1N{4x6oDLwsJihKk1NjRizsznM41t NHq0Xoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MA148 M1TXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzOOFghcA>? NIHEe3pKSzVyPUK4MlHjiIoEsfMAjVEvOCEQvHevcYw> MnTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 M2rxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TmRVQ5KGh? NIjZPHdKSzVyPUGxPE4x6oDLwsJihKkyNjJizsznM41t NUnOfFdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
MDA-MB-231 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nCdlQ5KGh? MX;JR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> NHPEd|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
NCI-ADR/RES  NH\EcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\yOFghcA>? NG\OdppKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t M2\PeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MA148 NWLpTWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH33T3E4OiCq MkPqTWM2OD1zMz635qCKyrIkgJmxMlIh|rypL33s MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
A549 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYO3NkBp M{fHdWlEPTB;NkSuN-KBkcLz4pEJNU4yKM7:Zz;tcC=> M3W3XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjrOWRkPzJiaB?= M{jjTGlEPTB;OUmuOgKBkcLz4pEJNU4yKM7:Zz;tcC=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
NCI-ADR/RES  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG3NkBp NGPYR25KSzVyPUO3MlTjiIoEsfMAjVEvPyEQvHevcYw> MoPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnidlA4OiCq MXvEUXNQ NX\qSZo3UUN3ME2xOVIvPDB7IN88US=> MnrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkGzNlMoRjJ2N{KxN|I{RC:jPh?=
NCI-H157 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi2U|B4PzJiaB?= NH[wenZFVVOR NHXhToxKSzVyPUi5Mlk4PyEQvF2= MlnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkGzNlMoRjJ2N{KxN|I{RC:jPh?=
PC9 M3\jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX0boVnPzJiaB?= MVnHR|UxRTdzLkdCtVkvPSEEtV2= M2jJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC3NkBp M4PpV2dEPTB;MUO2xtE{OS54INM1UeKh NXzxcJd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
PC9 MXTBdI9xfG:|aYOgRZN{[Xl? Ml74NVAxKML3TR?= MmDnO|IhcA>? NVWyTmFTcW6mdXPld{BieG:ydH;zbZM> Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549  Ml7DRZBweHSxc3nzJGF{e2G7 MYSxNFAhyrWP NVjhXVl[PzJiaB?= NHHib4hqdmS3Y3XzJIFxd3C2b4Ppdy=> MmD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmyOEBp MVnJR|ExRTFwNEe2JI5O MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR|OU[0N|c9N2F-
H1299 NH64UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmTXUzPCCq MVzJR|ExRTBwNESzJI5O NHH2dpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5OlQ{Pyd-MkSzPVY1Ozd:L3G+
HCC15 M2DZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO2NlQhcA>? MXXJR|ExRTBwM{S2JI5O M{HlXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
H157 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGyOEBp Ml7jTWMyOD1yLkixJI5O M1z3bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
A2780 NUXMTVM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf5TWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP NEO0OGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
A2780cisR NYLOS2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTR6LkpihKnDueLCiUOuPUDPxE1? M1LzVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780ZD0473R M3fGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfFfnlKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= NXnZOVlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl|PD;hQi=>
SKOV-3 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSzPJJKSzVyPUSzMlTjiIoEsfMAjVMvQSEQvF2= Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MEm2PVMoRjJ2MkC5Olk{RC:jPh?=
アッセイ
Methods Test Index PMID
Western blot pChK-2 / Chk-2 ; p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 ; p-p38 / p38 / Cleaved PARP / PARP 30049957
Immunofluorescence γH2AX 24348048
Growth inhibition assay Cell viability 24348048
体内試験

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

  • 細胞株:A2780, SKOV3, IGROV-1 and HX62
  • 濃度: 0-200 μM
  • 反応時間:72 hours
  • 実験の流れ:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

動物試験:

[1]

  • 動物モデル:The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • 投薬量:≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • 投与方法:Administered via i.p.

溶解度 (25°C)

体外

化学情報

分子量 371.25
化学式

C6H12N2O4Pt

CAS No. 41575-94-4
保管 2 years 4°C(in the dark) powder
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05395962 Recruiting Drug: Carboplatin|Drug: Bleomycin Vulvar Cancer IRCCS Azienda Ospedaliero-Universitaria di Bologna April 8 2022 Phase 2
NCT05181462 Recruiting Drug: Carboplatin|Drug: Gemcitabine|Drug: Nadunolimab Triple Negative Breast Cancer Cantargia AB|Spanish Breast Cancer Research Group January 11 2022 Phase 1|Phase 2
NCT05262985 Recruiting Drug: Durvalumab Patients With Advanced Treatment Naive LCNEC Elizabeth Dudnik|Assuta Medical Center January 31 2022 Phase 2
NCT04907968 Recruiting Drug: XMT-1536 (Upifitamab Rilsodotin)|Drug: Carboplatin Platinum-sensitive Ovarian Cancer (UPGRADE-A) Mersana Therapeutics|IQVIA Biotech June 11 2021 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?

回答
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: Carboplatin (NSC 241240)を買う | Carboplatin (NSC 241240) ic50 | Carboplatin (NSC 241240)供給者 | Carboplatin (NSC 241240)を購入する | Carboplatin (NSC 241240)費用 | Carboplatin (NSC 241240)生産者 | オーダーCarboplatin (NSC 241240) | Carboplatin (NSC 241240)化学構造 | Carboplatin (NSC 241240)分子量 | Carboplatin (NSC 241240)代理店